Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRON Disc Medicine	$57.79 +0.8%	$51.05	$30.82 ▼ $68.73	$1.99B	0.76	340,295 shs	613,868 shs
RLAY Relay Therapeutics	$3.65 +0.3%	$3.26	$1.78 ▼ $10.72	$624.06M	1.62	2.10 million shs	2.79 million shs
SDGR Schrodinger	$21.65 +1.9%	$21.99	$16.60 ▼ $28.47	$1.56B	1.58	925,182 shs	1.25 million shs
TVTX Travere Therapeutics	$16.51 -0.9%	$15.95	$7.93 ▼ $25.29	$1.48B	0.72	1.61 million shs	1.37 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRON Disc Medicine	+0.78%	-0.36%	+15.46%	+37.04%	+21.41%
RLAY Relay Therapeutics	+0.27%	-2.14%	+19.28%	+35.69%	-58.99%
SDGR Schrodinger	+1.88%	-0.28%	+3.69%	-15.92%	-6.56%
TVTX Travere Therapeutics	-0.90%	-0.24%	+17.18%	+10.66%	+60.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRON Disc Medicine	3.1234 of 5 stars	4.5	2.0	2.1	2.5	0.0
RLAY Relay Therapeutics	2.3922 of 5 stars	3.4	1.0	2.8	2.5	0.6
SDGR Schrodinger	1.8285 of 5 stars	3.4	1.0	1.9	1.7	0.6
TVTX Travere Therapeutics	3.7249 of 5 stars	4.4	5.0	2.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRON Disc Medicine	3.09	Buy	$96.70	67.33% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	384.02% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	51.27% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	94.69% Upside

Current Analyst Ratings Breakdown

Latest RLAY, IRON, TVTX, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
7/1/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/16/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
6/11/2025	IRON Disc Medicine	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
6/11/2025	TVTX Travere Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$30.00
6/11/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$35.00 ➝ $32.00
5/16/2025	TVTX Travere Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.85 per share	N/A
RLAY Relay Therapeutics	$10.01M	62.52	N/A	N/A	$4.65 per share	0.78
SDGR Schrodinger	$207.54M	7.65	N/A	N/A	$5.78 per share	3.75
TVTX Travere Therapeutics	$233.18M	6.29	N/A	N/A	$0.76 per share	21.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRON Disc Medicine	-$109.36M	-$3.92	N/A	N/A	N/A	N/A	-22.61%	-21.07%	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)

Latest RLAY, IRON, TVTX, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IRON Disc Medicine	-$1.17	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	TVTX Travere Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	N/A	N/A	N/A	$0.07 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRON Disc Medicine	0.04	37.65	37.65
RLAY Relay Therapeutics	N/A	19.96	19.96
SDGR Schrodinger	N/A	3.45	3.45
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRON Disc Medicine	83.70%
RLAY Relay Therapeutics	96.98%
SDGR Schrodinger	79.05%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IRON Disc Medicine	4.24%
RLAY Relay Therapeutics	4.87%
SDGR Schrodinger	8.60%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRON Disc Medicine	30	34.63 million	33.17 million	Not Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.08 million	Optionable

RLAY, IRON, TVTX, and SDGR Headlines

Recent News About These Companies

Research Analysts Set Expectations for TVTX FY2025 Earnings

1 hour ago | americanbankingnews.com

Wedbush Forecasts Reduced Earnings for Travere Therapeutics

July 17 at 6:31 AM | marketbeat.com

Q2 EPS Estimates for Travere Therapeutics Lowered by Wedbush

July 17 at 3:24 AM | americanbankingnews.com

Wedbush Expects Lower Earnings for Travere Therapeutics

July 16 at 7:16 AM | marketbeat.com

Emerald Advisers LLC Lowers Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 12, 2025 | marketbeat.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2025 | businesswire.com

109,542 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Penserra Capital Management LLC

July 8, 2025 | marketbeat.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | insidermonkey.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | msn.com

Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 815 Shares of Stock

July 3, 2025 | insidertrades.com

Q2 EPS Estimate for Travere Therapeutics Cut by Analyst

July 3, 2025 | marketbeat.com

Jula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

July 2, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

July 2, 2025 | prnewswire.com

1TVTX : Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews

July 2, 2025 | benzinga.com

Travere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC Wainwright

July 1, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Morningstar

June 29, 2025 | morningstar.comM

Travere Therapeutics Inc News (TVTX) - Investing.com

June 27, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 23, 2025 | globenewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

RLAY, IRON, TVTX, and SDGR Company Descriptions

Disc Medicine NASDAQ:IRON

$57.79 +0.45 (+0.78%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$57.80 +0.01 (+0.02%)

As of 07/17/2025 05:17 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Relay Therapeutics NASDAQ:RLAY

$3.65 +0.01 (+0.27%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.06 (+1.51%)

As of 07/17/2025 07:20 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Schrodinger NASDAQ:SDGR

$21.65 +0.40 (+1.88%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$21.86 +0.21 (+0.97%)

As of 07/17/2025 07:55 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Travere Therapeutics NASDAQ:TVTX

$16.51 -0.15 (-0.90%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$16.52 +0.00 (+0.03%)

As of 07/17/2025 04:34 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time